Amylyx Pharmaceuticals Inc
amylyx.comAmylyx Pharmaceuticals Inc (NASDAQ: AMLX) is a biopharmaceutical company focused on developing treatments for neurodegenerative and other serious diseases. Revenue is generated through product sales, recorded as net product revenue, though the 10-K filed March 3, 2026 does not disclose specific dollar figures in the available excerpts. The company's pipeline includes avexitide, AMX0035, AMX0114, and AMX0318, all at various stages of preclinical and clinical development. Amylyx operates at a net loss, funding operations partly through interest income on marketable securities and equity issuances, including a common stock financing completed during the year ended December 31, 2025. Co-Chief Executive Officers Joshua B. Cohen and Justin B. Klee lead the company alongside CFO James M. Frates. The filing covers the fiscal year ended December 31, 2025 and was signed March 3, 2026.
Products & Services
Pipeline candidates include avexitide, AMX0035, AMX0114, and AMX0318, all in preclinical or clinical development as of the 10-K filed March 3, 2026. AMX0035 has previously generated commercial product revenue.
Revenue Model
Product revenue (net) from commercial sales, supplemented by interest income on marketable securities. The company operates at a net loss and has financed operations through equity issuances, including a common stock offering completed in the fiscal year ended December 31, 2025.
Customers & Markets
Patients with neurodegenerative and other serious diseases. No specific customer concentration data or named customer types are disclosed in the available filing excerpts.
Geographic Exposure
Operates in the United States and other jurisdictions, with regulatory and data privacy obligations noted across the European Economic Area and the United Kingdom, as referenced in the 10-K filed March 3, 2026.
Financial Snapshot
Loading...
